Gene Therapy for Achromatopsia (CNGA3)
| Status: | Not yet recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 3 - 15 |
| Updated: | 12/1/2018 |
| Start Date: | March 2019 |
| End Date: | January 2022 |
| Contact: | MeiraGTx UK II Ltd |
| Email: | ocularinfo@meiragtx.com |
| Phone: | +44 (0)02 3866 4320 |
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children With Achromatopsia Owing to Defects in CNGA3
A clinical trial of AAV - CNGA3 retinal gene therapy for patients with achromatopsia
CNGA3 retinal gene therapy for patients with achromatopsia
Inclusion Criteria:
- Are aged 3 to 15 years
- Have achromatopsia confirmed by a retinal specialist (CI or PI)
Exclusion Criteria:
- Are females who are pregnant or breastfeeding
- Have participated in another research study involving an investigational medicinal
therapy for ocular disease within the last 6 months
- Have any other condition that the CI/PI considers makes them inappropriate for entry
into the trial
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials